文献速递神经肿瘤

WHO 2级和3级脑膜瘤放疗的长期结局与毒性:98例回顾性分析

Long-term outcomes and toxicity of radiotherapy for WHO Grade II and III meningiomas: a retrospective analysis of 98 patients.
PubMed 文献 · J Neurooncol · 2025-10-24

中位PFS为32.0个月,2年和5年PFS率分别为88.7%和66.0%;中位LC为33.0个月,2年和5年LC率分别为91.8%和72.2%。晚期严重毒性罕见,粒子治疗与较低的眩晕和头痛发生率相关。

要点

  • 高精度光子或粒子放疗对高级别脑膜瘤可获得较好的长期局部控制。
  • 中位PFS 32.0个月,5年PFS率66.0%;中位LC 33.0个月,5年LC率72.2%。
  • 晚期3级毒性罕见(n=3),粒子治疗与眩晕和头痛发生率较低相关。

核心结论

  • 高精度光子或粒子放疗在高grade脑膜瘤中实现了有效的长期控制且安全性良好。
  • 大多数不良反应轻微且可控,支持粒子治疗在减少特定晚期毒性方面的作用。

研究设计与样本

  • 中位年龄61岁(范围15-88),非颅底肿瘤占69.1%,颅底占30.9%。
  • 中位放疗剂量59.4 Gy(范围34-68),随访包括MRI评估局部控制、无进展生存、总生存和毒性(CTCAE v5)。

主要发现

  • 末次随访时94例(96.9%)存活,中位OS未达到,2年和5年生存率均为100%,8年生存率99%。
  • 中位PFS为32.0个月,2年和5年PFS率分别为88.7%和66.0%。
  • 中位LC为33.0个月,2年和5年LC率分别为91.8%和72.2%。
  • 40例(41.2%)出现疾病进展,其中30例为野内进展,22例为照射体积外进展。
  • 早期毒性主要为1-2级,最常见为脱发、乏力和头痛;晚期毒性包括头痛、癫痫、眩晕和放射性脑对比增强(RICE),3级晚期毒性罕见(n=3)。

临床怎么用

  • 对于WHO 2级和3级脑膜瘤,可考虑高精度光子或粒子放疗作为有效治疗选择。
  • 放疗后需通过MRI定期随访局部控制和无进展生存。
  • 粒子治疗可能减少眩晕和头痛等特定晚期毒性,选择放疗方式时可参考。

局限性

  • 回顾性研究设计。
  • 单中心数据可能影响结果的普遍性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This retrospective study evaluated outcomes and toxicity in patients with WHO Grade II and III meningiomas treated with modern photon or particle radiotherapy, with emphasis on skull base versus non-skull base tumors. METHODS: Ninety-seven patients received photon (58.2%) or particle therapy (41.8%). Median age was 61 years (range, 15-88). Tumor location was non-skull base in 69.1% and skull base in 30.9%. All patients underwent fractionated radiotherapy with a median dose of 59.4 Gy (range, 34-68). Follow-up included MRI and assessment of local control (LC), progression-free survival (PFS), overall survival (OS), and toxicity (CTCAE v5). RESULTS: At last follow-up, 94 patients (96.9%) were alive. Median OS was not reached, with survival rates of 100% at 2 and 5 years and 99% at 8 years. Median PFS was 32.0 months, with 2- and 5-year rates of 88.7% and 66.0%. Median LC was 33.0 months, with 2- and 5-year rates of 91.8% and 72.2%. Disease progression occurred in 40 patients (41.2%), including 30 in-field and 22 outside the irradiated volume. Early toxicities were mainly Grade I-II, most commonly alopecia, fatigue, and headache. Late toxicities were less frequent, including headache, seizures, vertigo, and radiation-induced cerebral contrast enhancement (RICE). Severe late toxicity (Grade III) was rare (n = 3). Particle therapy was associated with lower rates of vertigo and headache. CONCLUSION: High-precision photon and particle radiotherapy achieved effective long-term control with favorable safety in high-grade meningiomas. Most adverse effects were mild and manageable, supporting the role of particle therapy in reducing selected late toxicities.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Tas KT, Höft FS, Agolli L, et al. Long-term outcomes and toxicity of radiotherapy for WHO Grade II and III meningiomas: a retrospective analysis of 98 patients. J Neurooncol. 2025. PMID: 41134468. doi:10.1007/s11060-025-05255-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。